Yazen, a Lund-based digital weight-loss clinic founded in 2021, recently secured €3.1 million in funding to support its expansion across Europe. The round was led by Luminar Ventures. The startup’s mission is to combat obesity by offering a combination of lifestyle changes and modern medication through a digital platform. They aim to further develop their product, expand their customer base, and establish operations in additional markets.
As of now, Yazen operates in Sweden and has recently launched in Norway and Spain. Yazen’s team includes doctors, dietitians, psychologists, and personal trainers. The founders have experience in creating successful digital healthcare platforms like MinDoktor and Blodtrycksdoktorn.
Obesity is the major health problem of our time, costing the healthcare sector and society large amounts, not to mention the widespread human suffering it causes. Yazen has developed a clinically proven treatment method with lifestyle changes combined with the latest developments in weight loss medication, GLP-1 inhibitors. “We see substantial international potential and look forward to supporting the company,” says Magnus Bergman, co-founding partner of Luminar Ventures.
In Sweden alone, more than 1.3 million adults are obese and 52% of the population are overweight. Obesity is also the cause of many of the most common diseases such as heart disease, high blood pressure, type 2 diabetes, different forms of cancer and arthritis. Many countries in Europe have an even larger problem, with an even higher number of people being overweight. Yazen has 45 employees and strong monthly growth. The focus is now on growing at the same pace in the countries Yazen is now expanding to.
“We have already helped thousands of Swedes lose a total of several tons in weight and improved their quality of life as a result,” says Fredrik Meurling, co-founder and CEO of Yazen. “We see a massive 15% monthly growth in our number of patients, and this investment is very important for our continued development and European expansion.”
“The treatment of obesity is currently experiencing a global revolution: The development of GLP-1 inhibitors, in combination with lifestyle changes driven by an accessible digital platform gives our patients a completely new possibility to lose weight and maintain their new, healthy weight,” says Magnus Nyhlén, MD, co-founder and chairman of Yazen. “Yazen is well-prepared; with a competent team, an intelligent platform and this new financing, we are now ready to help more people all over Europe”
Click to read more funding news.
